Doximity heads into its fiscal second-quarter report with an awkward but well-telegraphed setup: the business is supposed to look sluggish this time. Management raised its full-year revenue outlook last quarter while warning that the September period would grow only about 1% against a brutal 23% comparison, with most new AI search revenue not landing until the December quarter. That makes this report less about the headline number and more about whether the AI story laid out three months ago is building on schedule.

Wall Street is looking for non-GAAP earnings of $0.34 per share on revenue of $170.7 million, essentially flat with the $0.33 and $168.5 million posted a year ago. The revenue estimate sits squarely in the middle of management's $170 million to $171 million guidance, so analysts are taking the company at its word rather than leaning on a beat. The whisper number of $0.36 is a touch above consensus, hinting that some investors expect the usual modest upside on profit, but the gap is small enough that the real bar is set by guidance commentary, not the quarter itself. Doximity topped its own revenue forecast by roughly 3% last time, and a similar cushion this quarter would push sales toward $175 million and quietly suggest the year-over-year trough is shallower than feared.

The more important tests sit beneath the top line. Signed health-system AI clients climbed from more than 100 to 140 to 165 over the past three quarters, helped by marquee wins at Northwestern, Penn Medicine and the University of Michigan. Continued growth in that count, along with signs that the Stanford and Harvard No Harm study ranking Doximity's clinical AI as the most accurate is converting into new deals, would validate the claim that safety is becoming a commercial edge. Investors should also look for an update on the first AI search revenue cohort, which spanned more than two dozen programs, and on whether the pipeline for larger, longer contracts is filling ahead of the next selling season. Usage metrics, including workflow engagement that was up more than 30% and AI prompts that rose 25% sequentially, need to keep compounding to justify the spending.

That spending is the other half of the bargain. Management framed fiscal 2027 as a year of heavy AI investment and trimmed its adjusted EBITDA outlook to a 47% margin from 49%. Non-GAAP gross margin has slid from 92% to 88% over four quarters on compute costs, and net revenue retention has eroded from 118% to 107%. Further margin slippage within the guided mid-to-high 80s range would be tolerable; a drop below it, or retention falling under 105%, would raise questions about whether pharma clients, whose budgets were described as tight but stabilizing, are pulling back faster than AI can offset. Free cash flow, which dipped to $40 million on collection timing, should rebound if that explanation holds.

Sentiment has swung sharply, moving from a clearly bearish reading before the last report to a moderately bullish one now. The stock tells a more cautious story, down 14.5% since the last release while the S&P 500 was roughly flat. At $33.24 it trades well above its 200-day average of $25.76 but sits about 17% below its post-earnings peak of $40, leaving room to rerate if the narrative firms up.

The central question is whether Doximity can show that its AI client wins, usage growth and nascent search monetization are on track to deliver the back-half acceleration that underpins the raised full-year outlook. Reaffirming or nudging up that $671 million to $681 million range while holding the margin line would keep the investment-year thesis intact; any wobble in the December-quarter setup would make this quiet quarter feel a lot louder.